Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sustol (Heron Therapeutics, Inc.)
- Development stage
- Unknown
- Lead developer
- Heron Therapeutics
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
Sustol (APF530) is an extended-release, subcutaneous formulation of the 5-HT3 receptor antagonist granisetron, developed by Heron Therapeutics (formerly A.P. Pharma). It utilizes the proprietary Biochronomer™ drug delivery system, which consists of a viscous tri(ethylene glycol) poly(orthoester) (TEG-POE) polymer. This system allows for the sustained release of granisetron over a period of at least five days from a single injection. Sustol is specifically indicated for use in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. By providing extended therapeutic concentrations, it addresses both the acute (0-24 hours) and delayed (24-120 hours) phases of chemotherapy-induced nausea and vomiting (CINV).
- Brand names
- Sustol
- Other names
- granisetron extended-release injectiongranisetron (Biochronomer)
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)
Beyond the preview
Go deeper on Sustol (Heron Therapeutics, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sustol (Heron Therapeutics, Inc.).